Patent Terms, Data Exclusivity, Compulsory Licensing, and Generic Entry Across 11 Markets Why South America Is the World’s Most Contested […]

A $28 Billion Opportunity Most Vendors Are Missing The 505(b)(2) pathway generates billions in annual drug revenue and runs on

Pharmaceutical executives routinely talk about patent cliffs as if they were acts of nature. They are not. The shape of

A strategic analysis for pharmaceutical companies, generic manufacturers, investors, and policy professionals The Indian Clock In most patent systems, the

Every major pharmaceutical patent war starts with a single form filed with the FDA. It is not a lawsuit. No

How litigation patterns, settlement timelines, and competitive pressure in biologics are rewriting the industry’s talent map — and what that

The Clock You Are Ignoring Every branded drug in the specialty channel has an expiration date that has nothing to

The Patent Clock Is a Sales Calendar Every drug patent that expires is a starting gun, not a finish line.

There’s a certain genre of drug question that never goes out of style: “Can this thing I’m already taking also